Edward Keystone

14PUBLICATIONS
54CO-AUTHORS
Pharmaceutical delivery technologiesToxicology (incl. clinical toxicology)Behavioural epidemiologyRespiratory diseasesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 17, 2024
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.

Miwa Haranaka, Takashi Eto, Takanori Tanaka

|Jun 21, 2024
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.

Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin

|Jun 19, 2024
Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis Cohort.

Brook Hadwen, Saverio Stranges, Janet E Pope

|May 14, 2023
Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI).

Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi

|Dec 19, 2022
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.

Arnaud Constantin, Roberto Caporali, Christopher J Edwards

|Sep 08, 2022
"From Where I Stand": using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ).

Susan J Bartlett, Vivian P Bykerk, Orit Schieir

Pageof 3

Frequent Collaborators

6 joint publications

Janet Pope

5 joint publications

Glen Hazlewood

5 joint publications

Carol Hitchon

4 joint publications

Susan J Bartlett